Ghulam Taha Khan

Ghulam Taha Khan

Auto-generated profile, based on publicly available information

Ghulam Taha Khan

Department of Medicine Dow University of Health Sciences Karachi Pakistan

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 October 2026 in Brain and Behavior
Verified
Journal Article
Open access
PDF file
SSShaheer Bin Shafiq
Shaheer Bin Shafiq
AUAmmad Uddin
Ammad Uddin
MHMuhammad Hussain
Muhammad Hussain
GKGhulam Taha Khan
Ghulam Taha Khan
MHMuhammad Hassan
Muhammad Hassan
MAMuhammad Ahmed
Muhammad Ahmed
Background: Posterior circulation ischemic stroke (PCIS) is associated with substantial morbidity and mortality, and the optimal intravenous thrombolytic strategy in this subgroup remains unclear. Methods: We searched databases for studies comparing intravenous tenecteplase with alteplase in adults with PCIS. The primary outcome was functional independence at 90 days (mRS 0–2). Secondary outcomes included other functional outcomes, reperfusion, hemorrhagic complications, and mortality. Results: Five studies involving 997 patients were included. Regarding efficacy outcomes, tenecteplase was associated with a significantly greater likelihood of achieving an ambulatory functional outcome at 90 days (mRS 0–3) [RR 1.29, 95% CI 1.03–1.60; p = 0.02] and improved pre‐EVT perfusion [RR 2.18, 95% CI 1.06–4.46; p = 0.03]. No significant differences were observed for excellent functional outcome (mRS 0–1) [RR 1.19, 95% CI 0.91–1.56; p = 0.20], functional independence (mRS 0–2) [RR 1.10, 95% CI 0.89–1.37; p = 0.39], or post‐EVT perfusion [RR 1.12, 95% CI 0.89–1.40; p = 0.34]. Regarding safety outcomes, no significant differences were observed between tenecteplase and alteplase for symptomatic intracranial hemorrhage (sICH) [RR 0.89, 95% CI 0.36–2.22; p = 0.81], any intracranial hemorrhage [RR 1.02, 95% CI 0.59–1.78; p = 0.94], parenchymal hematoma [RR 0.76, 95% CI 0.24–2.38; p = 0.64], or 90‐day mortality [RR 0.88, 95% CI 0.66–1.17; p = 0.39]. Conclusion: Tenecteplase may improve reperfusion and ambulatory recovery without increasing hemorrhagic complications or mortality compared with alteplase in PCIS, although larger PCIS‐specific studies are needed.

9 September 2026 in Annals of Pharmacotherapy
Verified
Journal Article
Closed access
TITaha Ibrahim
Taha Ibrahim
MBMuhammad Burhan
Muhammad Burhan
SSShaheer Bin Shafiq
Shaheer Bin Shafiq
AWAli Wajahat
Ali Wajahat
OSOwais Sanaullah
Owais Sanaullah
IHIbrahim Nagmeldin Hassan
Ibrahim Nagmeldin Hassan
Background: Fremanezumab, a calcitonin gene-related peptide monoclonal antibody, is approved for migraine prevention, yet evidence specific to episodic migraine remains limited. We synthesized randomized evidence on its efficacy and safety. Methods: Following Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines (PROSPERO CRD420261385104), we systematically searched PubMed, Embase, and Scopus from inception to June 5, 2026, for placebo-controlled randomized controlled trials (RCTs) evaluating fremanezumab for episodic migraine prevention. Primary outcomes were the ≥50% responder rate and change in monthly migraine days. Random-effects meta-analyses were performed, and risk of bias was assessed using the Cochrane RoB 2 tool. Results: Four RCTs including 1764 participants were included. Fremanezumab significantly increased the ≥50% responder rate (risk ratio: 1.81, 95% CI: 1.53-2.15) and reduced monthly migraine days (mean difference: −1.98, 95% CI: −2.93 to −1.03), headache days, acute medication-use days, and migraine-related disability. Overall safety was comparable to placebo, with no significant differences in treatment-emergent adverse events, serious adverse events, or treatment discontinuations; injection-site induration occurred more frequently with fremanezumab. Relevance to Patient Care and Clinical Practice: This meta-analysis strengthens the evidence supporting fremanezumab as an effective and generally well-tolerated preventive therapy for episodic migraine. The demonstrated reductions in migraine frequency, disability, and acute medication use, together with flexible monthly and quarterly dosing, support its use in appropriately selected patients and may facilitate individualized treatment decisions by clinicians and pharmacists. Although the inclusion of pediatric data expands the current evidence base, these findings should be interpreted cautiously because they are derived from a single randomized trial. Conclusion: Fremanezumab is an effective and generally well-tolerated preventive treatment for episodic migraine. Evidence is robust in adults, whereas pediatric findings remain preliminary and warrant confirmation in future randomized trials.